Loss of Medicare reimbursement for PancraGEN®
The company states it cannot continue offering the test after CMS ended coverage, removing a core product from its portfolio.
- Scope
- PancraGEN® and first-line fluid chemistry testing
- Materiality
- high
Interpace Biosciences, Inc.
Interpace Biosciences, Inc. is a U.S.-based clinical diagnostics company that develops and performs proprietary molecular tests used to support cancer-related decision-making, with a focus on pancreatic and other oncology-related conditions. The company generates revenue primarily from clinical services billed to third-party payers and Medicare, and its business model is tightly linked to reimbursement coverage and laboratory test volumes.
11,6 %
62,3 %
63,5 %
−17,5 %
1.94
1.72
| % | |
|---|---|
| Clinical diagnostic testing | 100% Proprietary laboratory assays and molecular tests performed on patient specimens. |
The company sells its clinical services into the healthcare reimbursement system, so its direct customers are largely...
- Ordering physicians and specialistsprimary
They order proprietary tests to support diagnosis and treatment decisions, especially in oncology and pancreatic disease.
- Medicare beneficiariesprimary
A key payer base for PancraGEN® and related testing; reimbursement coverage directly determines whether the test can be offered.
- Commercial insurers and third-party payersprimary
They reimburse clinical services and affect realized revenue through coverage policies and collection rates.
- Hospitals and outpatient clinicssecondary
They submit specimens and rely on the company’s lab results to support patient management.
Interpace Biosciences operates as a U.S.-centric diagnostics business, with revenue driven by domestic clinical testing...
- •Revenue is primarily generated in the United States
- •Medicare policy changes directly affect test availability and demand
- •U.S. laboratory regulation and LDT oversight are key operating constraints
- •Domestic payer mix drives collection rates and revenue recognition
- •No meaningful international operating footprint was disclosed
Management is focused on preserving liquidity, improving margins, and resizing the cost base after the loss of Medicare...
01
Restructure the cost baseshort-term
The loss of PancraGEN® reimbursement requires a smaller operating footprint to preserve profitability and cash.
02
Maintain liquidityshort-term
The company needs sufficient cash to fund operations while reimbursement and revenue visibility remain uncertain.
03
Replace lost test revenuemedium-term
Future growth depends on sustaining clinical service revenue and developing new molecular solutions.
The most important company-specific risk is reimbursement dependence: CMS ended coverage for PancraGEN®, which...
Liquidity and refinancing pressure
The company relies on cash, collections, and external financing, but capital access is limited after delisting.
- Scope
- Working capital and future growth funding
- Materiality
- high
Secured lender foreclosure rights
If obligations are not repaid on time, substantially all assets could be foreclosed upon.
- Scope
- Asset base and going-concern flexibility
- Materiality
- high
Regulatory and reimbursement change
LDT oversight, payer coverage, and pricing rules can alter whether tests are reimbursed profitably.
- Scope
- U.S. clinical diagnostics operations
- Materiality
- high
Third-party supply dependence
The company depends on external suppliers for materials used in testing, which can affect service continuity.
- Scope
- Laboratory consumables and test inputs
- Materiality
- medium
Revenue recognition and net realizable value estimates
Can shift revenue and gross margin between periods
Contractual allowances and payer mix
Affects net revenue and receivables valuation
Restructuring and severance accruals
Impacts operating expenses and cash outflows
Stock-based compensation
Affects operating income and adjusted EBITDA reconciliation
Genprex, Inc.
GNPX · Pharmaceutical Preparations
PRECIGEN, INC.
PGEN · Pharmaceutical Preparations
Erasca, Inc.
ERAS · Pharmaceutical Preparations
PharmaCyte Biotech, Inc.
PMCB · Biological Products, (No Diagnostic Substances)
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
: 28/04/2026